Massive Bio, a New York-based company with an AI tool that matches cancer patients with clinical trials appropriate to their cancer diagnosis, is planning bolt-on acquisitions following a Series B round likely to raise between USD 25m–USD 30m, co-founder and CEO Selin Kurnaz said. The health-tech company recently raised a
November 2nd, 2022: Massive Bio, a leader in AI-powered cancer clinical trial enrollment, has published the second issue of Massive Bio magazine. The publication, which had a successful debut in August, features a variety of content for cancer patients and their families, clinicians, and the business community. Featured content in
November 17th 2022: Massive Bio, which uses artificial intelligence to match cancer patients to clinical trials, launches “I Have Cancer,” a social media campaign to raise cancer awareness. In keeping with its mission to improve the lives of cancer patients, Massive Bio aims to raise mass awareness about cancer,
November 2nd, 2022: Massive Bio, a leader in AI-powered cancer clinical trial enrollment, has published the second issue of Massive Bio magazine. The publication, which had a successful debut in August, features a variety of content for cancer patients and their families, clinicians, and the business community. Featured content in